DE69809959D1 - Neue taxanderivate - Google Patents
Neue taxanderivateInfo
- Publication number
- DE69809959D1 DE69809959D1 DE69809959T DE69809959T DE69809959D1 DE 69809959 D1 DE69809959 D1 DE 69809959D1 DE 69809959 T DE69809959 T DE 69809959T DE 69809959 T DE69809959 T DE 69809959T DE 69809959 D1 DE69809959 D1 DE 69809959D1
- Authority
- DE
- Germany
- Prior art keywords
- new
- taxan derivatives
- derivatives
- new taxan
- cycloalkyloxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 125000002541 furyl group Chemical group 0.000 abstract 1
- -1 piperazino Chemical group 0.000 abstract 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
- 125000004665 trialkylsilyl group Chemical group 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
- C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/108—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epoxy Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP9251804A JPH1192468A (ja) | 1997-09-17 | 1997-09-17 | 新規なタキサン誘導体 |
| PCT/JP1998/004180 WO1999014209A1 (fr) | 1997-09-17 | 1998-09-17 | Nouveaux derives de taxane |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69809959D1 true DE69809959D1 (de) | 2003-01-16 |
| DE69809959T2 DE69809959T2 (de) | 2003-07-24 |
Family
ID=17228181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69809959T Expired - Fee Related DE69809959T2 (de) | 1997-09-17 | 1998-09-17 | Neue taxanderivate |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US6136808A (de) |
| EP (1) | EP1022277B1 (de) |
| JP (1) | JPH1192468A (de) |
| KR (1) | KR100514809B1 (de) |
| CN (1) | CN100369908C (de) |
| AT (1) | ATE229012T1 (de) |
| AU (1) | AU730174B2 (de) |
| BR (1) | BR9812218A (de) |
| CA (1) | CA2302445C (de) |
| DE (1) | DE69809959T2 (de) |
| DK (1) | DK1022277T3 (de) |
| ES (1) | ES2189234T3 (de) |
| PT (1) | PT1022277E (de) |
| WO (1) | WO1999014209A1 (de) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU758418B2 (en) * | 1997-12-19 | 2003-03-20 | Kabushiki Kaisha Yakult Honsha | Taxane derivatives |
| ATE342260T1 (de) * | 1999-05-28 | 2006-11-15 | Bristol Myers Squibb Co | Halbsynthese von paclitaxel mit hilfe von dialkyldichlorsilanen |
| US6649632B2 (en) | 2000-02-02 | 2003-11-18 | Fsu Research Foundation, Inc. | C10 ester substituted taxanes |
| AU783422B2 (en) | 2000-02-02 | 2005-10-27 | Florida State University Research Foundation, Inc. | C10 carbamoyloxy substituted taxanes as antitumor agents |
| NZ514073A (en) * | 2000-02-02 | 2004-02-27 | Univ Florida State Res Found | Taxane formulations having improved solubility |
| AU7007001A (en) | 2000-06-22 | 2002-01-02 | Nitromed Inc | Nitrosated and nitrosylated taxanes, compositions and methods of use |
| CA2354471A1 (en) * | 2001-07-31 | 2003-01-31 | Florida State University Research Foundation, Inc. | C10 ester substituted taxanes |
| US7351542B2 (en) | 2002-05-20 | 2008-04-01 | The Regents Of The University Of California | Methods of modulating tubulin deacetylase activity |
| WO2004002468A1 (en) | 2002-06-26 | 2004-01-08 | Medigene Oncology Gmbh | Method of producing a cationic liposomal preparation comprising a lipophilic compound |
| JP2007525188A (ja) | 2003-05-16 | 2007-09-06 | インターミューン インコーポレイテッド | 合成ケモカイン受容体リガンドおよびその使用方法 |
| HN2005000054A (es) | 2004-02-13 | 2009-02-18 | Florida State University Foundation Inc | Taxanos sustituidos con esteres de ciclopentilo en c10 |
| CA2597682A1 (en) * | 2005-02-14 | 2006-08-24 | Florida State University Research Foundation, Inc. | C10 cyclopropyl ester substituted taxane compositions |
| CA2607940C (en) | 2005-05-18 | 2009-12-15 | Aegera Therapeutics Inc. | Bir domain binding compounds |
| US8168216B2 (en) | 2006-03-22 | 2012-05-01 | Medigene Ag | Treatment of triple receptor negative breast cancer |
| BRPI0711591A2 (pt) | 2006-05-16 | 2011-11-16 | Aegera Therapeutics Inc | composto de ligação de domìnio bir da iap |
| KR100847331B1 (ko) * | 2006-12-14 | 2008-07-21 | 한미약품 주식회사 | 도세탁셀의 제조방법 및 이에 사용되는 중간체 |
| EP2276755A4 (de) * | 2008-03-31 | 2011-05-04 | Univ Florida State Res Found | C(10)-ethylester- und c(10)-cyclopropylester-substituierte taxane |
| WO2010005721A2 (en) * | 2008-06-16 | 2010-01-14 | Bind Biosciences, Inc. | Drug loaded polymeric nanoparticles and methods of making and using same |
| EP2859916B1 (de) | 2008-05-22 | 2017-11-29 | Galera Labs, LLC | Antimitotika mit Superoxid Dismutase Mimetika für die Kombinationstherapie gegen Krebs |
| WO2010005850A1 (en) | 2008-07-08 | 2010-01-14 | The J. David Gladstone Institutes | Methods and compositions for modulating angiogenesis |
| KR101014438B1 (ko) * | 2008-09-26 | 2011-02-14 | 동아제약주식회사 | 탁산 유도체의 제조방법 |
| SG182724A1 (en) | 2010-02-12 | 2012-08-30 | Pharmascience Inc | Iap bir domain binding compounds |
| US9532972B2 (en) | 2012-02-07 | 2017-01-03 | University Of Central Florida Research Foundation, Inc. | Increasing taxane sensitivity in cancer cells |
| US9181343B2 (en) | 2012-07-19 | 2015-11-10 | Redwood Bioscience Inc. | Antibody specific for CD22 and methods of use thereof |
| CA2890190A1 (en) | 2012-11-12 | 2014-05-15 | Redwood Bioscience, Inc. | Compounds and methods for producing a conjugate |
| CA2901115A1 (en) | 2013-02-15 | 2014-08-21 | The Regents Of The University Of California | Heterodimeric conditionally active chimeric antigen receptor and methods of use thereof |
| CN105358531B (zh) | 2013-03-14 | 2017-11-14 | 利兰-斯坦福大学初级学院的董事会 | 线粒体醛脱氢酶‑2调节剂和其使用方法 |
| JP6745218B2 (ja) | 2013-11-27 | 2020-08-26 | レッドウッド バイオサイエンス， インコーポレイテッド | ヒドラジニル−ピロロ化合物及び複合体を生成するための方法 |
| PL3107899T3 (pl) | 2014-02-19 | 2021-01-25 | Aviv Therapeutics, Inc. | Policykliczne amidy wiążące mitochondrialną dehydrogenazę aldehydową-2 (aldh2) i ich zastosowanie w leczeniu nowotworów |
| RU2016141267A (ru) | 2014-03-21 | 2018-04-24 | Эббви Инк. | Антитела против egfr и конъюгаты антитело-лекарственное средство |
| EP3122376A4 (de) | 2014-03-27 | 2017-12-20 | The Brigham and Women's Hospital, Inc. | Metabolisch aktivierte wirkstoffkonjugate zur überwindung der resistenz in der krebstherapie |
| EP3373977A4 (de) | 2015-11-12 | 2019-07-17 | The Board of Trustees of the Leland Stanford Junior University | Zellenpenetrierende, guanidiniumreiche oligophosphotriester zur wirkstoff- und sondenfreisetzung |
| TWI760319B (zh) | 2015-12-30 | 2022-04-11 | 杏國新藥股份有限公司 | 乳癌治療 |
| EP3231421A1 (de) | 2016-04-11 | 2017-10-18 | Greenaltech, S.L. | Verwendungen eines carotenoids bei der behandlung oder prävention von durch stress verursachten störungen |
| JP2019515677A (ja) | 2016-04-26 | 2019-06-13 | アール．ピー．シェーラー テクノロジーズ エルエルシー | 抗体複合体ならびにそれを作製および使用する方法 |
| EP3463308B1 (de) | 2016-06-01 | 2021-12-01 | Servier IP UK Limited | Formulierungen von polyalkylen-oxid-asparaginase und verfahren zur herstellung und verwendung davon |
| EP3468599A2 (de) | 2016-06-08 | 2019-04-17 | AbbVie Inc. | Anti-cd98-antikörper und antikörperwirkstoffkonjugate |
| CN109563167A (zh) | 2016-06-08 | 2019-04-02 | 艾伯维公司 | 抗b7-h3抗体和抗体药物偶联物 |
| US20200002432A1 (en) | 2016-06-08 | 2020-01-02 | Abbvie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
| AU2017279554A1 (en) | 2016-06-08 | 2019-01-03 | Abbvie Inc. | Anti-B7-H3 antibodies and antibody drug conjugates |
| TWI762487B (zh) | 2016-06-08 | 2022-05-01 | 美商艾伯維有限公司 | 抗-b7-h3抗體及抗體藥物結合物 |
| TW201825087A (zh) | 2017-01-05 | 2018-07-16 | 杏國新藥股份有限公司 | 胰臟癌治療 |
| MX2019008503A (es) | 2017-01-18 | 2019-09-13 | F1 Oncology Inc | Receptores de antigenos quimericos contra axl o ror2 y metodos de uso de los mismos. |
| EP3388082A1 (de) | 2017-04-13 | 2018-10-17 | Galera Labs, LLC | Kombinationskrebsimmuntherapie mit makrocyclischem pentaaza-ringkomplex |
| JP2021530507A (ja) | 2018-07-18 | 2021-11-11 | マンザニータ ファーマシューティカルズ，インク． | 神経細胞に抗がん剤を送達するためのコンジュゲート、その使用方法及び製造方法 |
| AU2020253449A1 (en) | 2019-04-02 | 2021-11-18 | Kenjockety Biotechnology, Inc. | Efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto |
| BR112022013870A2 (pt) | 2020-01-29 | 2022-09-13 | Kenjockety Biotechnology Inc | Anticorpos anti-mdr1 e usos dos mesmos |
| US20230212305A1 (en) | 2020-06-04 | 2023-07-06 | Kenjockety Biotechnology, Inc. | Anti-abcg2 antibodies and uses thereof |
| AU2021283080A1 (en) | 2020-06-04 | 2022-12-15 | Kenjockety Biotechnology, Inc. | ABCG2 efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto |
| CN116490522A (zh) | 2020-09-02 | 2023-07-25 | 肯乔克蒂生物技术股份有限公司 | 抗abcc1抗体及其应用 |
| US20240010747A1 (en) | 2020-11-13 | 2024-01-11 | Kenjockety Biotechnology, Inc. | Anti-mrp4 (encoded by abcc4 gene) antibodies and uses thereof |
| AR124681A1 (es) | 2021-01-20 | 2023-04-26 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
| WO2023114658A1 (en) | 2021-12-13 | 2023-06-22 | Kenjockety Biotechnology, Inc. | Anti-abcb1 antibodies |
| WO2023159220A1 (en) | 2022-02-18 | 2023-08-24 | Kenjockety Biotechnology, Inc. | Anti-cd47 antibodies |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4942184A (en) * | 1988-03-07 | 1990-07-17 | The United States Of America As Represented By The Department Of Health And Human Services | Water soluble, antineoplastic derivatives of taxol |
| US5227400A (en) * | 1991-09-23 | 1993-07-13 | Florida State University | Furyl and thienyl substituted taxanes and pharmaceutical compositions containing them |
| US5250683A (en) * | 1991-09-23 | 1993-10-05 | Florida State University | Certain substituted taxanes and pharmaceutical compositions containing them |
| US5243045A (en) * | 1991-09-23 | 1993-09-07 | Florida State University | Certain alkoxy substituted taxanes and pharmaceutical compositions containing them |
| FR2687151B1 (fr) * | 1992-02-07 | 1994-03-25 | Rhone Poulenc Rorer Sa | Nouveaux derives de la baccatine iii et de la desacetyl-10 baccatine iii, leur preparation et les compositions pharmaceutiques qui les contiennent. |
| JPH08253465A (ja) * | 1995-03-17 | 1996-10-01 | Dai Ichi Seiyaku Co Ltd | 四環性化合物 |
| FR2742753B1 (fr) * | 1995-12-22 | 1998-01-30 | Rhone Poulenc Rorer Sa | Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent |
| BR9710366A (pt) * | 1996-07-15 | 1999-08-17 | Yakult Honsha Kk | Derivados de taxane e drogas que os contêm |
| US6017935A (en) * | 1997-04-24 | 2000-01-25 | Bristol-Myers Squibb Company | 7-sulfur substituted paclitaxels |
-
1997
- 1997-09-17 JP JP9251804A patent/JPH1192468A/ja active Pending
-
1998
- 1998-09-17 ES ES98943019T patent/ES2189234T3/es not_active Expired - Lifetime
- 1998-09-17 CN CNB988092395A patent/CN100369908C/zh not_active Expired - Fee Related
- 1998-09-17 BR BR9812218-5A patent/BR9812218A/pt not_active Application Discontinuation
- 1998-09-17 PT PT98943019T patent/PT1022277E/pt unknown
- 1998-09-17 US US09/508,092 patent/US6136808A/en not_active Expired - Fee Related
- 1998-09-17 AU AU90950/98A patent/AU730174B2/en not_active Ceased
- 1998-09-17 AT AT98943019T patent/ATE229012T1/de not_active IP Right Cessation
- 1998-09-17 DK DK98943019T patent/DK1022277T3/da active
- 1998-09-17 EP EP98943019A patent/EP1022277B1/de not_active Expired - Lifetime
- 1998-09-17 KR KR10-2000-7002637A patent/KR100514809B1/ko not_active IP Right Cessation
- 1998-09-17 WO PCT/JP1998/004180 patent/WO1999014209A1/ja active IP Right Grant
- 1998-09-17 CA CA002302445A patent/CA2302445C/en not_active Expired - Fee Related
- 1998-09-17 DE DE69809959T patent/DE69809959T2/de not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ATE229012T1 (de) | 2002-12-15 |
| KR100514809B1 (ko) | 2005-09-13 |
| AU9095098A (en) | 1999-04-05 |
| BR9812218A (pt) | 2000-07-18 |
| ES2189234T3 (es) | 2003-07-01 |
| EP1022277A1 (de) | 2000-07-26 |
| CA2302445A1 (en) | 1999-03-25 |
| DE69809959T2 (de) | 2003-07-24 |
| EP1022277B1 (de) | 2002-12-04 |
| WO1999014209A1 (fr) | 1999-03-25 |
| US6136808A (en) | 2000-10-24 |
| CN100369908C (zh) | 2008-02-20 |
| AU730174B2 (en) | 2001-03-01 |
| DK1022277T3 (da) | 2003-01-06 |
| CA2302445C (en) | 2008-04-29 |
| EP1022277A4 (de) | 2000-07-26 |
| CN1270587A (zh) | 2000-10-18 |
| PT1022277E (pt) | 2003-04-30 |
| JPH1192468A (ja) | 1999-04-06 |
| KR20010023937A (ko) | 2001-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69809959T2 (de) | Neue taxanderivate | |
| ATE282630T1 (de) | Dolastatin-derivate | |
| SG86971A1 (en) | 2-arylthiazole derivatives and pharmaceutical composition thereof | |
| PT705833E (pt) | Derivado de dc-89 | |
| ATE138919T1 (de) | Pyranylcyanoguanidinderivate | |
| DE69628804T2 (de) | Substitutierte heterozyclische Derivate als CRF Antagonisten | |
| MA22797A1 (fr) | Procedes de preparation de nouveaux azaindoles | |
| EP0358190A3 (de) | Polysiloxane mit sterisch gehinderten Gruppen | |
| DE69813605D1 (de) | Benzofuranderivate | |
| ATE176470T1 (de) | Xanthinderivate | |
| ATE271045T1 (de) | Sauerstoffhaltige heterocyclische verbindungen | |
| EP1044971A4 (de) | Taxan-derivate | |
| TW347389B (en) | Taxoids, their preparation and pharmaceutical compositions containing them | |
| ATE168679T1 (de) | Neue tetracyclische verbindungen | |
| PT679082E (pt) | Derivados de taxano em c10 e composicoes farmaceuticas | |
| ES2159729T3 (es) | Derivados de pirazolo(1,5-a)pirimidina. | |
| BG105247A (en) | N-substituted azabicycloheptane derivatives, production and use thereof | |
| EP0418655A3 (en) | Conjugated gamma-hydroxybutenolide compounds and antiulcer agents containing the same as an effective ingredient | |
| DE69815347D1 (de) | Tetrahydrofuranderivate | |
| MX9704976A (es) | Derivados de 1,2,3-benzotiadiazol. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8339 | Ceased/non-payment of the annual fee |